Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (965)	5/13/2004 4:05:55 PM
From: Jibacoa	Read Replies (1) \| Respond to of 1005

Well, the "news" seems to have helped on erasing yesterday's and the earlier today loss.<g> New Publication Highlights Anti-Metastatic Properties of Introgen's INGN 241 in Preclinical Models of Lung Cancer Thursday May 13, 1:30 pm ET AUSTIN, Texas, May 13 /PRNewswire-FirstCall/ -- Data appearing in the current issue of Molecular Therapy describe the mechanism by which expression of the mda-7 gene, the active component of INGN 241, inhibits invasion and migration of human lung cancer cells. Introgen Therapeutics, Inc. (Nasdaq: INGN - News) is developing INGN 241, currently in Phase 2 clinical trials for metastatic melanoma and has completed Phase 1 - 2 trials in multiple solid tumor indications. Researchers at Introgen and The University of Texas M. D. Anderson Cancer Center conducted the studies and the data are reported in a paper titled "Ectopic Production of MDA-7/IL-24 Inhibits Invasion and Migration of Human Lung Cancer Cells." Additional findings from these studies are scheduled to be presented at the 7th Annual Meeting of the American Society of Gene Therapy, June 2nd - 6th (Abstract #954). "A key challenge in treating cancer is the spread of disease from the primary tumor to disparate sites within the body," said Sunil Chada, Ph.D., Introgen's director of Research and Development. "The results of these studies demonstrate that INGN 241 inhibits the migration and invasion of lung cancer cells. Moreover, the data also define the specific proteins and molecular pathways through which this effect is mediated, which may help to expand our understanding of the molecular biology of metastasis. Our clinical and preclinical experience with INGN 241 suggests that this multi-functional product candidate may have significant utility in treating primary tumors as well as preventing the spread of cancer to other parts of the body. Reducing the number and rate of metastases may positively impact the long-term outcomes of cancer patients." In these studies, conducted in the laboratory of Dr. Rajagopal Ramesh, Assistant Professor in the Department of Thoracic and Cardiovascular Surgery at M. D. Anderson Cancer Center, the impact of INGN 241 (Ad-mda7) protein on the migration and invasion of human lung cancer cells was examined in two cultured cell lines and in animals implanted with human lung tumors. Cell culture studies demonstrated that expression of MDA-7 protein resulted in a significant decrease in cancer cell migration compared with controls. Further analysis of treated and untreated cells detected changes in several migration- related proteins, providing a molecular mechanism for the observed reduction in migration. When treated or un-treated human lung cancer cells were implanted into mice, the INGN 241-treated animals had significantly fewer lung tumor nodules, indicating a significant inhibition of metastasis. This data was validated using a non-viral method for mda-7 gene delivery in a model of human lung tumor metastasis -- again significant inhibition of metastasis was observed. biz.yahoo.com

To: tuck who wrote (965)	9/14/2005 6:17:35 PM
From: tuck	Respond to of 1005

>>SOUTH SAN FRANCISCO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc., (Nasdaq: PTIE - News) a biopharmaceutical company, today reported positive Phase III results with Remoxy, an abuse-resistant form of long-acting oxycodone. In this study, the safety and efficacy of Remoxy was compared against placebo in osteoarthritic patients with moderate-to-severe chronic pain. This Phase III study design was randomized, double-blinded and enrolled 209 patients in over 20 U.S. clinical sites. Patients were treated with Remoxy 20 mg or matching placebo twice daily over a 4-week study period. Patient demographics and baseline pain scores were similar in both arms. The primary objective of this study was to evaluate pain relief. Results demonstrated a statistically significant difference (p<0.05) between Remoxy and placebo in the study's primary endpoint: percent decrease in pain scores from baseline to final study visit, measured with a standard Likert Pain Scale. The secondary objective of this study was to evaluate patients' quality of life. Results demonstrated statistically significant differences (p<0.05) between Remoxy and placebo in each component of the WOMACTM Osteoarthritis Index, in physical function measured by a standard SF-12® Health Survey and in patients' self-reported Quality of Analgesia. "We're delighted to announce these positive Phase III study results with Remoxy," said Remi Barbier, president and chief executive officer. "These positive data allow us to forge ahead with Remoxy's clinical development. We also believe these data open doors to various commercial options for Remoxy, such as launching this drug by ourselves or with a pharmaceutical firm that shares our vision of the market potential for this drug." No drug-related safety issues were noted in this study. As expected, opioid-related adverse events were higher in the Remoxy arm compared to the placebo arm. Adverse events typically associated with chronic opioid use include nausea/vomiting, dizziness, pruritus (itching), and somnolence/sedation. Also as expected, the patient drop-out rate was higher in the Remoxy arm (35%) compared to the placebo arm (24%). Patients in the Remoxy arm dropped mainly due to opioid-related adverse events. Patients in the placebo arm dropped mainly due to lack of efficacy. Pain Therapeutics' next step with Remoxy is to conduct a large, pivotal Phase III registration study that can support a New Drug Application under an FDA filing strategy known as 505(b)(2). The Company expects to initiate this study by year-end 2005. About Oxycodone Abuse Oxycodone is a strong opioid painkiller and is the active drug ingredient in Remoxy. Oxycodone is also the active drug ingredient in Oxycontin®, a brand name drug with sales of nearly $2 billion in 2004. Long-acting versions of oxycodone are widely used to treat moderate-to-severe chronic pain. However, drug abusers can easily extract oxycodone from Oxycontin® tablets (and all other marketed versions of long-acting oxycodone) in order to induce a quick and powerful euphoric high. Abusers of long-acting oxycodone risk respiratory depression, which can be fatal, and opioid addiction. According to government data, oxycodone abuse resulted in over 20,000 visits to emergency rooms and hundreds of deaths in 2002. Please visit the U.S. Drug Enforcement Administration's website ( www.usdoj.gov/dea ) for more information. About Remoxy Remoxy is an investigational drug candidate to treat severe chronic pain. The FDA has not yet evaluated the merits, safety or efficacy of Remoxy. We are developing this drug as an abuse-resistant alternative to marketed forms of long-acting oxycodone. Remoxy has a sticky, high-viscosity mass that resists injection or snorting. Published data show that freezing, crushing or submerging Remoxy in high-proof alcohol for hours at a time releases just a fraction of oxycodone compared to Oxycontin® at time points when abusers presumably expect to get high. We believe these collective properties of Remoxy may deter recreational abuse or accidental patient misuse of long acting oxycodone.<< snip Don't know if FDA would want a head to head trial versus Oxycontin or what. The stock popped into the $7.20 area on the news, and has drifted down to the higher $6s since, not getting much support from an upgrade Monday. I haven't followed this one in a while, but it might take another look here. Cheers, Tuck